Oslo, 1 April 2020: Ultimovacs ASA (“Ultimovacs”, ticker ULTIMO), a pharmaceutical company developing novel immunotherapies against cancer, announces that the Board in Ultimovacs ASA has approved the Annual Report for 2019. Please find a PDF version of the report enclosed. The Annual Report is also available at the company’s website: www.ultimovacs.com
This information is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.
For further information, please see www.ultimovacs.com or contact:
Øyvind Kongstun Arnesen, CEO oeyvind.arnesen@ultimovacs.com, +47 469 33 810
Hans Vassgård Eid, CFO hans.eid@ultimovacs.com, +47 469 19 822